1. Home
  2. CRS vs RPRX Comparison

CRS vs RPRX Comparison

Compare CRS & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Carpenter Technology Corporation

CRS

Carpenter Technology Corporation

HOLD

Current Price

$430.01

Market Cap

21.3B

Sector

Industrials

ML Signal

HOLD

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

HOLD

Current Price

$49.46

Market Cap

19.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRS
RPRX
Founded
1910
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.3B
19.5B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
CRS
RPRX
Price
$430.01
$49.46
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
5
Target Price
$419.75
$51.40
AVG Volume (30 Days)
655.4K
2.5M
Earning Date
04-29-2026
05-06-2026
Dividend Yield
0.20%
1.90%
EPS Growth
100.54
N/A
EPS
7.29
1.78
Revenue
$2,157,700,000.00
$2,378,193,000.00
Revenue This Year
$9.21
$38.63
Revenue Next Year
$10.50
$4.73
P/E Ratio
$58.68
$28.12
Revenue Growth
20.03
5.06
52 Week Low
$204.47
$31.97
52 Week High
$459.18
$50.47

Technical Indicators

Market Signals
Indicator
CRS
RPRX
Relative Strength Index (RSI) 54.88 59.14
Support Level $297.11 $35.34
Resistance Level $459.18 $50.08
Average True Range (ATR) 19.85 0.87
MACD -2.63 -0.06
Stochastic Oscillator 55.64 61.59

Price Performance

Historical Comparison
CRS
RPRX

About CRS Carpenter Technology Corporation

Carpenter Technology Corp supplies specialty metals to a variety of end markets, including aerospace and defense, industrial machinery and consumer durables, medical, and energy, among others. The company's reportable segments include; Specialty Alloys Operations and Performance Engineered Products. It generates maximum revenue from the Specialty Alloys Operations segment. The SAO segment is comprised of the company's alloy and stainless steel manufacturing operations. This includes operations performed at mills predominantly in Reading and Latrobe, Pennsylvania, and surrounding areas as well as South Carolina and Alabama. Geographically, the company derives its maximum revenue from the United States and the rest from Europe, Asia Pacific, Mexico, Canada, and other regions.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: